retatrutide triple agonist glp-1 gip glucagon phase 3 2025 Diagram showing the mechanism of action of retatrutide Retatrutide 10mg Triple Agonist |
Description
The brain: the least clear picture for GLP-1 therapy This is where the story gets genuinely complicated
Starting with a low dose and titrating gradually can help minimise these effects
In the stomach, it slows gastric emptying, meaning food stays in your digestive system longer and you feel satisfied with smaller meals
Hypertension is the most common preventable risk factor for CVDs (including coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, and peripheral artery disease), chronic kidney disease, and cognitive impairment, and also the main single factor for deaths and disability worldwide (133)
The compound was well tolerated with no evidence of genotoxicity, indicating its potential as a therapeutic agent for type 2 diabetes and obesity in humans
Eligibility depends on specific criteria and local NHS commissioning arrangements
